9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 601–700 of 975
Rao, V. V., & Shanti, K. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2024.108938 · Cited by 4
Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020
Chlup, R., Kaňa, R., Hanáčková, L., Zálešáková, H., & Doubravová, B. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96237 · Cited by 5
¿La insulina es un todoterreno?
Cuenca, A. M. C. (2021) · doi:10.52102/insulina/art-4 · Cited by 3
Cómo podemos optimizar la insulinización
Cosiales, P. B. (2021) · doi:10.52102/insulina/art-3 · Cited by 3
Sarkisova, F., Lessing, C., & Stretton, C. (2022) · Journal of Primary Health Care · doi:10.1071/hc21122 · Cited by 5
Antsiferov, M. B., Demidov, N. A. D., Balberova, M. A., Safronova, T. I., Mishra, O. A. M., & Magomedova, S. G. (2022) · Diabetes Mellitus · doi:10.14341/dm12809 · Cited by 7
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date
Rizvi, A. A., Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Almahmeed, W. A., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2094771 · Cited by 4
Joubert, M., Briant, A. R., Kessler, L., Fall-Mostaine, F., Dubois, S. G., Guerci, B., Schoumacker-Ley, L., Reznik, Y., & Parienti, J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01302-3 · Cited by 5
Prelude to PATHWEIGH: pragmatic weight management in primary care
Wild, J. L., Kaizer, A. M., Willems, E., Kramer, E. S., & Perreault, L. (2022) · Family Practice · doi:10.1093/fampra/cmac092 · Cited by 4
Langaas, H. C., Salvesen, Ø. O., Dyrkorn, R., Blix, H. S., & Spigset, O. (2023) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2023.2222781 · Cited by 4
Abdelmannan, D. K., AlBuflasa, M., Ajlouni, H. K., Zidan, M. A., Rahman, F., Farooqi, M. H., & Caballero, A. E. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111045 · Cited by 5
Wen, W., Lee, Y., Hwu, D., & Chang, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15465 · Cited by 5
Mahmoud, F., Mueller, T., Mullen, A. B., Sainsbury, C. A. R., Rushworth, G. F., & Kurdi, A. B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15584 · Cited by 5
“8,9 Consistently, this study showed that metformin was by far the most commonly used first-line ADD for newly treated patients in each studied year.”
BackgroundAmbery, P., Zajac, G., Almquist, J., Prothon, S., Astbury, C., Brown, M. N., Nemes, S., Nsabimana, J., Edman, K., Öberg, L., et al. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16082 · Cited by 4
“11,12 Moreover, patients receiving corticosteroids, and in particular those with type 2 diabetes mellitus, are at great risk of developing high glycaemic variability, which is linked to worse outcomes.”
Joshi, N., Qasim, M. Z., Kanumilli, S., Shaukat, F., Kumar, A., Mahek, F., Khalid, S., Zeeshan, M., Shaik, M. Y., Nishat, S. M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002494 · Cited by 6
“By reducing blood vessel damage caused by hyperglycemia and promoting stable blood glucose levels through medication and lifestyle changes, diabetic individuals can lower their risk of cardiovascular disease (CVD) [38,39] .”
BackgroundKrishnan, A., Schneider, C. V., Arkenau, H., Mauro, E., Forner, A., Butsch, W. S., Walsh, D., & Alqahtani, S. A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100370 · Cited by 13
Yen, F., Wei, J. C., Ko, F., Huang, Y., Yip, H., Tsai, F., Hwu, C., & Hsu, C.-C. (2025) · ERJ Open Research · doi:10.1183/23120541.00919-2024 · Cited by 4
“Clinical studies on DPP-4 inhibitors have provided favourable clinical profiles compared with other antidiabetic drugs used for diabetes management [12].”
HADDAD, J. A., Annabi, F. A., Abbasi, H., Al-Samen, M. A. A., Ammari, F. L., Haddad, F., Haddad, S. E., Jaradat, M., Khassawneh, A., Khatib, N., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01718-7 · Cited by 4
“The American Diabetes Association recommends that GLP‑1 RAs or SGLT2is be prescribed to patients with T2D and established ASCVD (eASCVD) or who are at risk for ASCVD, regardless of baseline glycated hemoglobin (HbA1c), HbA1c target, or metformin use [10].”
Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
Calçada, M. B., Fernandes, L. G. D. M., Costa, R. S., Montezinho, S., Duarte, F. M., Frutuoso, L., & Freitas, A. R. (2021) · Clinics and Practice · doi:10.3390/clinpract11020031 · Cited by 5
Perez-Belmonte, L. M., Ricci, M., Sanz‐Cánovas, J., Cobos-Palacios, L., Lopez-Carmona, M. D., Ruiz-Moreno, M. I., Millán‐Gómez, M., Bernal-López, M. R., Jansen‐Chaparro, S., & Gómez‐Huelgas, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092013 · Cited by 4
Kim, D., Yu, J., Wang, E. K., Lee, S., Kim, J. S., Hwang, J., Ku, C. R., Cho, Y. H., & Lee, E. J. (2021) · Biomedicines · doi:10.3390/biomedicines9070745 · Cited by 4
Resident opinions of diabetes management in training: a survey
Healy, A. M., Uhrig, J. L., Shubrook, J. H., Aung, N. L., & Sadhu, A. (2021) · Journal of Osteopathic Medicine · doi:10.1515/jom-2021-0035 · Cited by 5
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 8
Lane, W. S., Faurby, M. D., Husemoen, L. L. N., Markovich, D. L., Rathor, N., & Block, C. E. M. D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01165-0 · Cited by 5
Moffatt, E. K., Wargo, R., Johnson, C., & Kawaguchi‐Suzuki, M. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1544 · Cited by 4
Harada, M., Nishi, T., Maeda, T., Tanno, K., Nishiya, N., & Arima, H. (2021) · SSM - Population Health · doi:10.1016/j.ssmph.2021.100961 · Cited by 5
Clinical Impact of GLP‐1 receptor agonists in veterans receiving basal‐bolus insulin
Hopton, O. M., Waterbury, N. V., Egge, J. A., & Lund, B. C. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2648 · Cited by 4
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Mishriky, B. M., Cummings, D. M., & Powell, J. R. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.03.012 · Cited by 5
Bae, J. P., KADZIOLA, Z. A., Liu, D., Chinthammit, C., Boye, K. S., & Mather, K. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01289-x · Cited by 5
Owlia, F., Zarezadeh, F., Jambarsang, S., & Kazemipoor, M. (2022) · International Journal of Dentistry · doi:10.1155/2022/6197070 · Cited by 4
Günhan, H. G. (2022) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2022.202 · Cited by 4
Alem, M. M. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11549 · Cited by 6
Study of Hypoglycemic Activity of Novel 9-N-alkyltetrahydroberberine Derivatives
Khvostov, M. V., Gladkova, E. D., Борисов, С. А., Fedotova, M. S., Zhukova, N., Marenina, M. K., Meshkova, Y. V., Luzina, O. A., Tolstikova, T. G., & Salakhutdinov, N. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214186 · Cited by 6
Seetharaman, R., Advani, M., Mali, S. N., & Pawar, S. R. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0003 · Cited by 4
Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors
Panikar, S. S., Keltee, N., Berry, N.-K., Shmuel, S., Fisher, Z. T., Brown, E. L., Zidel, A., Mabry, A., & Pereira, P. M. R. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265248 · Cited by 5
Park, S., Jeong, H. E., Bea, S., Yu, O. H. Y., Cho, Y. M., You, S. C., Man, K. K. C., & Shin, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15221 · Cited by 5
Kwon, S., Ha, J. H., Kim, D. K., Kim, Y. S., Lim, C. S., Chang, H., Lee, J. P., & Park, J. (2021) · International Wound Journal · doi:10.1111/iwj.14370 · Cited by 3
Krysiak, R. G., Basiak, M., Szkróbka, W., & Okopień, B. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00289-1 · Cited by 4
Volpe, S., Tortorella, C., Solfrizzi, V., & Piazzolla, G. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s321340 · Cited by 4
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 11
Classer les diabètes qui surviennent chez l’adulte : plus on y pense, plus c’est confus
Monnier, L., & Colette, C. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.09.008 · Cited by 4
Silva‐Cardoso, J., Fonseca, C., Franco, F., Morais, J., Ferreira, J., & Brito, D. A. (2021) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2021.11.017 · Cited by 4
HRAMIAK, I. M., Gerstein, H. C., Leiter, L. A., Yale, J., BAJAJ, H. S., Stewart, J. A., Toutounji, M.-J., & Harris, S. B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14787 · Cited by 3
Davies, M. J., Rosenstock, J., Ali, A., Russell-Jones, D. L., Souhami, E., PALMER, K. D., Ji, C. F., Niemoeller, E., & SKOLNIK, N. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14543 · Cited by 4
Rizzo, M., Cosentino, F., & Mantzoros, C. S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2108400 · Cited by 4
İşleyen, E. K., Özdemir, İ. N., & Yoldemır, Ş. A. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-03916-5 · Cited by 4
Non-oncologic to oncologic drug: A systematic review of drug repurposing in cancer
Dhanush, Y., & Ganesh, V. S. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04822-4 · Cited by 5
“Biguanide-derived hypoglycemic pharmacotherapy, Metformin maintains preeminence as the initial therapeu - tic intervention for non-insulin-dependent diabetes mellitus according to consensus recommendations from the Ameri - can Diabetes Association and international clinical practice algorithms [64].”
Nelson, L. A., Bergner, E. M., Adler, A., Yoon, C., Mieras, K., Simeone, E., Lema-Driscoll, J., Everett, B. M., Wexler, D. J., & Mayberry, L. S. (2026) · Medical Care · doi:10.1097/mlr.0000000000002246 · Cited by 3
“11 Both are FDA-approved and recommended by the American Diabetes Association 8 and American College of Cardiology 9 for the treatment of patients with T2D and ASCVD.”
Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis
Klein, K. R., Menacher, A., Buse, J. B., Mann, J. F. E., Tuttle, K. R., Kvist, K., Andersen, M. R., Mayrdorfer, M., & Lingvay, I. (2026) · Diabetes Care · doi:10.2337/dc26-0112 · Cited by 3
Aleppo, G., Bode, B. W., & Carlson, A. L. (2022) · Clinical Diabetes · doi:10.2337/cd21-0056 · Cited by 3
Ogawa, R., Sugimoto, C., Hamada, A., Ninomiya, K., Ina, S., Yamaguchi, Y., Kumagai, H., & Kumagaı, H. (2023) · Sustainable Food Proteins · doi:10.1002/sfp2.1006 · Cited by 3
SGLT ‐2 inhibitors and GLP ‐1 receptor agonists for Type 2 diabetes
Davila, E., & McCormack, J. P. (2024) · Academic Emergency Medicine · doi:10.1111/acem.14895 · Cited by 3
Rangwala, H. S., Fatima, H., Ali, M., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., & Abbas, S. R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01412-8 · Cited by 3
Vlacho, B., Molló, À., Gratacòs, M., Mata‐Cases, M., Rubinat, E., Berenguera, A., Cos, X., Franch‐Nadal, J., & Mauricio, D. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.05.001 · Cited by 4
Kim, N. H., Moon, J. S., Ha, K. H., Kim, J., Kwon, K.-E., Kim, S. G., & Kim, D. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112405 · Cited by 4
Heart Failure and Diabetes: Perspective of a Dangerous Association
Favaloro, L. E., Ratto, R., & Musso, C. (2021) · Current Hypertension Reviews · doi:10.2174/1573402117666210406111927 · Cited by 4
Effective and convenient treatment of Xultophy with lower doses for elderly diabetic patient
Bando, H., Yasuoka, T., Hayashi, K., Miki, K., Kamoto, A., Hamai, M., Matsumoto, Y., Shinomiya, M., Kawaguchi, R., Ootani, M., et al. (2021) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2021.09.00305 · Cited by 3
Cardiovascular Disease in Patients with Diabetes: A Comparison of Professional Society Guidelines
Sarkar, S., Salazar, I. M. C., Tibuakuu, M., & Blumenthal, R. S. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210820105514 · Cited by 3
SGLT-2-gátló kezelés diabeteses és nem diabeteses vesebetegségben
Molnár, G. A., Sélley, E., & Wittmann, I. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.14 · Cited by 3
Integration of Clinical and Scientific Principles in the Teaching of Drug-Drug Interactions
Kim, R. E., Morningstar-Kywi, N., & Haworth, I. S. (2021) · Medical Science Educator · doi:10.1007/s40670-021-01395-8 · Cited by 3
Person-Centered Medication Therapy for Diabetes in Older Adults: A Practical Review
Wilson, E. (2021) · Journal of Gerontological Nursing · doi:10.3928/00989134-20210908-02 · Cited by 3
Next-gen therapeutics to spare and expand beta-cell mass
Bolla, A. M., Usuelli, V., Nasr, M. B., Frigerio, S., Loretelli, C., D’Addio, F., & Fiorina, P. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.001 · Cited by 3
Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease
Swanner, A. A., Hawley, C. E., Li, K., Triantafylidis, L. K., Li, J., & Paik, J. M. (2022) · Clinical Diabetes · doi:10.2337/cd21-0078 · Cited by 3
Sukhareva, O. Y., Zuraeva, Z. T., & Shamhalova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12864 · Cited by 4
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
Use of SGLT2 inhibitor/metformin fixed dose combination in Korea
Choi, H. E., Lee, J., Je, N. K., & Jeong, K. H. (2022) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2022.32.1.13 · Cited by 3
Optimal Type 2 Diabetes Mellitus Management and Active Ageing
Calabrese, A. M., Calsolaro, V., Rogani, S., Okoye, C., Caraccio, N., & Monzani, F. (2021) · Endocrines · doi:10.3390/endocrines2040047 · Cited by 4
Ações de prevenção e controle de diabetes na atenção primária no Amazonas
de Leon, E. B., Fernandes, L. S., Campos, H. L. M., & Almeida, F. A. (2022) · Revista Brasileira de Atividade Física & Saúde · doi:10.12820/rbafs.27e0271 · Cited by 4
Pantalone, K. M., Rajpathak, S. N., Ji, X., Jin, J., Weiss, T., Bauman, J. M., Radivoyevitch, T., Kattan, M. W., Zimmerman, R. S., & Misra‐Hebert, A. D. (2022) · Diabetes Spectrum · doi:10.2337/ds22-0031 · Cited by 3
Nazu, N. A., Wikström, K., Lamidi, M., Lindström, J., Tirkkonen, H., Rautiainen, P., & Laatikainen, T. K. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01889-3 · Cited by 3
Васильевич, Д. Р., Mayorov, A. Y., Каронова, Т. Л., Parfenova, T. M., Макаренко, И. Е., Magruk, M. A., Alpenidze, D., Kovalik, V. V., Zinnatulina, B. R., Grigorjeva, I. V., et al. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0232 · Cited by 3
Singh, H., Arora, E., Narula, S., Singla, M., Otaal, A., & Sharma, J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2216279 · Cited by 3
Ku, E. J., & Oh, T. K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01437-x · Cited by 3
Peddi, D. R., Pallekonda, H., & Reddy, V. (2023) · Cureus · doi:10.7759/cureus.42775 · Cited by 9
Qiang, W., Li, M., Song, S., Dong, R., Zhang, T., Kou, X., Wu, Y. F., Wang, Z., Liu, J., Liu, J., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s468070 · Cited by 3
Sunagawa, K., Hirai, K., Sunagawa, S., Kamiya, N., Komesu, I., Sunagawa, Y., Sunagawa, H., Nakachi, K., Hirai, A., Ookawara, S., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s471535 · Cited by 4
Ranting in 2021: Could This Get Any Worse?
Hirsch, I. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0001 · Cited by 3
Acute abdomen as a side-effect of sodium–glucose co-transporter 2 inhibitors in diabetic patients
Kietaibl, A.-T., Fasching, P., Glaser, K. S., & Petter‐Puchner, A. H. (2021) · British journal of surgery · doi:10.1093/bjs/znab390 · Cited by 3
Diabetes Mellitus Type 1 During COVID-19: Psychological Symptoms and Eating Attitudes
Benioudakis, E. S., Karlafti, E., Georgiou, E. D., Kalaitzaki, A. E., Kaiafa, G. D., Savopoulos, C. G., & Didangelos, T. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220516105920 · Cited by 3
Westergaard, N., Tarnow, L., & Vermehren, C. (2021) · Pharmaceuticals · doi:10.3390/ph14090899 · Cited by 3
Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
Кононенко, И. В., & Smirnova, O. M. (2021) · Diabetes Mellitus · doi:10.14341/dm12768 · Cited by 4
Decrease in the efficacy of glucagon-like peptide-1 receptor agonists: what is the reason?
Кушнарьова, Н. М., Zinych, О. В., Korpachev, V. V., Ковальчук, А., Prybyla, О. В., & Shyshkan-Shyshova, К. О. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.8.2021.246799 · Cited by 3
Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes
Eby, E. L., Kelly, N., Hertzberg, J. K., Blodgett, M., Stubbins, C., Patel, R. H., Meadows, E. S., Benneyworth, B. D., & Faries, D. E. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221098057 · Cited by 4
Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
Chiu, N., Aggarwal, R., & Bhatt, D. L. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026297 · Cited by 4
“The most recent American Diabetes Association 2021 recommendations suggest the use of GLP- 1 agonists in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease independent of HbA1c or metformin use.”
BackgroundAlmalki, M., Aldesokey, H., Alkhafaji, D., Alsheikh, A., Braae, U. C., Lehrskov, L. L., Magawry, W., Yahia, M., & Haroun, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02366-0 · Cited by 5
and, J. T., & Boyle, J. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch2 · Cited by 3
Biomarkers and Precision Medicine in Diabetes
Tye, S. C., Provenzano, M., & Heerspink, H. J. L. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch30 · Cited by 3
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_6 · Cited by 3
Weeda, E. R., Burnette, B., Rowe, S. M., Haas, S., Zecopoulos, A., & Alnewais, M. E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14606 · Cited by 3
Behrendt, C., Heidemann, F., Meyer, A. J., Werra, U. E. M., & Rother, U. (2024) · Gefässchirurgie · doi:10.1007/s00772-024-01086-9 · Cited by 2
Zhang, Q., Liu, H., Zhang, J., Ouyang, Y., Fu, X., & Xie, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1501990 · Cited by 4
Li, H., & Guan, Z. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01516-8 · Cited by 2
Feasibility of the Implementation of Tools for Heart Failure Risk Prediction
Wang, M. C., Dolan, B., Huang, X., Freaney, P. M., Freed, B. H., Vega, L., Markoski, N., Wainright, A. E., Kane, B. J., Seegmiller, L. E., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102004 · Cited by 3
Alyabsi, M. S., Almousa, L., Alqarni, A. H., Aldawsari, A., Alnasser, L. A., & Almutairi, A. F. (2025) · Current Therapeutic Research · doi:10.1016/j.curtheres.2025.100809 · Cited by 2
“16 This trend aligns with findings from previous studies.”
Ahmed, A. E., Tan, Z., El-Radi, W. A., & Rajamani, K. K. (2025) · Cureus · doi:10.7759/cureus.92175 · Cited by 5
“The current guideline of the ADA suggests that early introduction of insulin should be considered in T2DM patients with HbA1c levels exceeding 10% or BG ≥ 300 mg/dL [40].”
Lee, E. J., Jeong, I. S., Kim, I. J., Cho, Y. H., & Kim, Y. J. (2021) · International Journal of Nursing Practice · doi:10.1111/ijn.13012 · Cited by 4
Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?
Katsiki, N., & Fonseca, V. A. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108075 · Cited by 2
Individualización del tratamiento de la diabetes mellitus tipo 2
Llavero-Valero, M., Ugalde, B., Huguet, I., & Triviño, V. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.12.003 · Cited by 6
Singh, H., Joshi, D., Narula, S., Singla, M., Rohilla, R., & Singh, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2053111 · Cited by 2
Francisco, M. D., Magnaye, F. M., Molina, A. J. R., & Sandoval, M. A. (2022) · Acta Medica Philippina · doi:10.47895/amp.v56i6.2992 · Cited by 2
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.